Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Podoplanin: An emerging cancer biomarker and therapeutic target
SUNY Stony Brook, NY 11794 USA.
Univ Birmingham, England.
Natl Canc Ctr, Japan; Univ Tokyo, Japan.
Natl Canc Ctr, Japan; Univ Tokyo, Japan.
Show others and affiliations
2018 (English)In: Cancer Science, ISSN 1347-9032, E-ISSN 1349-7006, Vol. 109, no 5, p. 1292-1299Article, review/survey (Refereed) Published
Abstract [en]

Podoplanin (PDPN) is a transmembrane receptor glycoprotein that is upregulated on transformed cells, cancer associated fibroblasts and inflammatory macrophages that contribute to cancer progression. In particular, PDPN increases tumor cell clonal capacity, epithelial mesenchymal transition, migration, invasion, metastasis and inflammation. Antibodies, CAR-T cells, biologics and synthetic compounds that target PDPN can inhibit cancer progression and septic inflammation in preclinical models. This review describes recent advances in how PDPN may be used as a biomarker and therapeutic target for many types of cancer, including glioma, squamous cell carcinoma, mesothelioma and melanoma.

Place, publisher, year, edition, pages
WILEY , 2018. Vol. 109, no 5, p. 1292-1299
Keywords [en]
cancer; chemotherapy; c-type lectin-like receptor 2; podoplanin
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:liu:diva-148655DOI: 10.1111/cas.13580ISI: 000434071400002PubMedID: 29575529OAI: oai:DiVA.org:liu-148655DiVA, id: diva2:1219978
Note

Funding Agencies|Proteintech; Fox Rothschild; VWR; Sentrimed; Rowan University; Osteopathic Heritage Foundation; New Jersey Health Foundation; JSPS KAKENHI [25461674, 24659185, 16H05311, 2617H06356]; National Cancer Center Research and Development Fund [23-A-12]; Foundation for the Promotion of Cancer Research; 3rd Term Comprehensive 10-Year Strategy for Cancer Control; Advanced Research for Medical Products Mining Programme of the National Institute of Biomedical Innovation (NIBIO); British Heart Foundation [RG/13/18/30563]; Project for Cancer Research and Therapeutic Evolution (P-CREATE) [17cm0106205 h0002]; Medical Research and Development Programs Focused on Technology Transfer, Acceleration Transformative Research for Medical Innovation (ACT-MS) from the Japan Agency for Medical Research and Development (AMED) [17im0210607 h0002]

Available from: 2018-06-18 Created: 2018-06-18 Last updated: 2018-07-03

Open Access in DiVA

fulltext(519 kB)14 downloads
File information
File name FULLTEXT01.pdfFile size 519 kBChecksum SHA-512
76fc9b93b3105ed1c03ca64d6c78311b80304901c39997efd763a37418d25371d288166e78593144bfdc3356d7195de7c46abf58e9c5d50f5804f616f9242db4
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Jensen, Lasse
By organisation
Division of Cardiovascular MedicineFaculty of Medicine and Health SciencesDepartment of Clinical Pharmacology
In the same journal
Cancer Science
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar
Total: 14 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 68 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf